Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Mo | UK sees 70% increase in phase I advanced therapy clinical trials in 2024 | ||
Mo | Datapharm expands into US market through partnership with phactMI | ||
Do | Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials | ||
Do | Actinogen boosts trial with Cambridge Cognition's digital suite | ||
Mi | Owlstone Medical announces $27 million USD first close in Series E financing round | ||
Mi | Oxford Drug Design achieves in vivo validation for novel cancer treatment | ||
14.01. | Pheno Therapeutics granted trial authorisation for MS candidate | ||
14.01. | Grifols pioneers high-tech analysis of plasma bank to detect Parkinson's disease | ||
13.01. | AI set to revolutionise pharmaceutical R&D says GlobalData | ||
13.01. | Gilead and LEO Pharma partner to develop oral STAT6 program | ||
09.01. | New therapy hope for prostate cancer patients | ||
09.01. | NICE recommends olaparib for BRCA-mutated breast cancer treatment | ||
08.01. | Cambridge Cognition highlights positive Cantab results | ||
08.01. | Angelini Ventures co-leads Series A financing in Neumirna Therapeutics | ||
07.01. | Novartis gene therapy set to enhance SMA treatment | ||
07.01. | Merck unveils new cyber-physical trust platform at CES 2025 | ||
06.01. | New prostate cancer test cuts biopsies by 50% in US | ||
06.01. | Amgen's lung cancer treatment gets conditional approval | ||
03.01. | NHS Confederation welcomes social care commission announcement | ||
03.01. | FDA approves Sequana Medical's Alfapump for ascites treatment | ||
02.01. | EC approves Rybrevant with Lazcluze for advanced lung cancer | ||
02.01. | UK regulator warns against buying weight-loss medicines without prescription | ||
17.12.24 | MindMed begins phase 3 study of MM120 for anxiety disorder | ||
17.12.24 | German cancer centre treats first patient with Elekta Evo | ||
16.12.24 | CSL receives positive opinion for garadacimab in hereditary angioedema |